A Phase 2 trial in immune thrombocytopenia reported that mezagitamab significantly increased platelet counts in affected patients, according to the coverage. In ITP, patients experience low platelet levels due to immune-mediated destruction and impaired platelet production, driving bleeding risk. The update adds to the clinical momentum around Fc-engineered or receptor-targeting antibodies aimed at achieving faster, clinically meaningful platelet responses compared with existing therapies.